Latest news for Arion Group (OTC:ARGC) Stock

Arion Group Corp is currently a start-up company exploring various manufacturing and distribution business opportunities in the dietary ingredient and nutritional supplement industry.

Arion Group Corp

Not surprisingly, shares of Palantir Technologies Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) staged a <a href="https://www.benzinga.com/markets/equities/24/06/39420511/stock-of-the-day-why-palantir-may-be-about-to-reverse">meaningful reversal</a> off of a resistance level. This type of price action occurs frequently in the market. 
Sometimes, the sellers who created the resistance with their sell orders start to undercut each other's prices. They know the buyers will go to whoever has the lowest price. This can push the price down.
But other times, shares move higher through the resistance. This is called a &#8220;breakout&#8221; and these can have bullish implications. 
It's why Palantir is our Stock of the Day. As you can see on the chart, a breakout could be underway.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="615" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/08134359/1-4-1024x615.png" alt="Is Palantir (PLTR) Breaking Out?" class="wp-image-424712" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/08134359/1-4-1024x615.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/08134359/1-4-300x180.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/08134359/1-4-768x462.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/08134359/1-4.png 1045w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Also: <a href="https://www.benzinga.com/news/24/07/39666072/whats-going-on-with-palantir-stock-today">What&#8217;s Going On With Palantir Stock Today?</a>
Stocks move higher when the bulls can't find all the shares they wish to buy at the current price levels. There isn't enough supply, or sell orders, in the market. As a result, if they want to acquire shares, they are forced to push the price higher to draw sellers into the market. This makes the stock trend upwards.
When a stock reaches a resistance level, the tide turns. The buyers can buy all the stock they want without pushing the price higher. And as we have seen, sometimes stocks can reverse after they reach resistance.
But sometimes they trade higher through the resistance. This &#8220;breakout&#8221; isn't just symbolic. It illustrates an important supply and demand dynamic. It means the people who created the resistance with their sell orders have finished or canceled their orders. Either way, they are out of the market.
With this supply out of the way, the stage could be set for another move higher. The bulls may not be able to buy all the shares they wish to at the current levels. They may be forced to push the price higher once again to get new sellers interested. This could be about to happen with <a href="https://www.benzinga.com/quote/PLTR">Palantir</a>.
Successful traders know that in the stock market, some price levels are more important than others. And when they know which ones are, they can get insight into when a new trend will begin. The profits will follow.

Read Next: • <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39665665/apple-microsoft-meta-google-stocks-hit-52-week-highs-which-is-the-best-investment">Apple, Microsoft, Meta, Google Stocks Hit 52-Week Highs: Which Is The Best Investment?</a>
Photo: Shutterstock

Technicals

Tech

PLTR

Stock of the Day: Why Palantir May Be About To Move Higher

WIIM

MBUU

Malibu Boats shares are trading lower after Truist Securities downgraded the stock from Buy to Hold and announced a $32 price target.

The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) is up over 3.5% in the last 30 days, an impressive feat amid <a href="https://www.benzinga.com/top-stories/24/07/39652831/whartons-jeremy-siegel-implores-jerome-powell-to-signal-september-rate-cuts-we-are-in-a-slowing-econ">signs of slowing</a> in the U.S. economy. Despite investor optimism, only 17% of S&amp;P 500 components have outperformed the index in the past month, a historic low.
The Data: A <a href="https://x.com/KobeissiLetter/status/1810332300766228769">post</a> on X relayed data from The Compound News.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">How concentrated has this market become? Just 17% of S&amp;P 500 stocks have outperformed the index over the last 30 days, the lowest share in at least a decade. In other words, only 85 stocks in the S&amp;P 500 have had higher returns than the index itself over the last month. By… <a href="https://t.co/ETPAG2ZCi3">pic.twitter.com/ETPAG2ZCi3</a>
&mdash; The Kobeissi Letter (@KobeissiLetter) <a href="https://twitter.com/KobeissiLetter/status/1810332300766228769?ref_src=twsrc%5Etfw">July 8, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to the data, just 17% of S&amp;P 500 members — approximately 85 companies — outperformed the overall index in the past 30 days. The 10-year average for overperformance is 49%, far above today&#8217;s figure.
This is the lowest number for 30-day outperformance in at least a decade. The figure reached above 50% for extended periods in mid-to-late 2022, late 2023 and early 2024.
Tesla Inc, Adobe Inc., Apple Inc and Amazon.com Inc are among the few companies to outperform the index, according to <a href="https://benzinga.com/pro">Benzinga Pro</a>. Nike Inc, Danaher Corp and CVS Health Corp are a few of the biggest underperformers.
Why it Matters: The data reflects the fact that just a few technology-focused stocks have a historically outsized impact on the market. Big Tech has outperformed companies in other industries.
High concentration is a double-edged sword: while investors with S&amp;P 500 exposure stand to benefit even more from tech&#8217;s continued rally, they also face increased risk if the market sours on the tech play. <a href="https://www.goldmansachs.com/intelligence/pages/is-the-sp-too-concentrated.html">According</a> to Goldman Sachs Research, the S&amp;P 500 has historically rallied in the year following periods of peak concentration.
There are some concerns that the standard S&amp;P 500 has become overvalued compared to its more diversified, Invesco S&amp;P 500 Equal Weight ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSP#NYSE">RSP</a>) counterpart.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/06/39508567/active-fund-managers-bet-these-6-stocks-will-trade-near-all-time-highs">Active Fund Managers Bet These 6 Stocks Will Trade Near All-Time Highs</a></li>
</ul>
Photo: Shutterstock

Broad U.S. Equity ETFs

Econ #s

Rydex ETF Trust Rydex S&P Equal Weight ETF

Just 17% Of S&P 500 Stocks Outperform The Index: What Does That Mean For The Market?

PARA

Paramount Global shares are trading lower after the company  announced that they have entered into a definitive agreement with Skydance to form "New Paramount"

Pseudonymous Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) analyst Decode provided a technical analysis of Bitcoin&#8217;s current performance, which suggests $100,000 may be on the table until the <a href="https://www.benzinga.com/money/bitcoin-price-prediction">end of the cycle</a>.
What Happened: Decode&#8217;s <a href="https://x.com/decodejar/status/1809924570973151387">analysis</a> is based on the Elliott Wave theory, which doesn't directly correlate with Bitcoin's halving cycles or any other specific intervals but represents the market sentiment resulting from these factors.
Four primary waves have been completed and the fifth is expected to be completed soon. This suggests Bitcoin is heading into a major blow-off top shortly.
If Bitcoin closes the weekly candle above $56,522, no further downside is expected. If it fails to do so, a drop to the low $50,000s may be possible.
Decode believes that Bitcoin could reach $100,000 or even higher before the cycle ends, as it is currently moving up in a clean log channel, with the recent drop tapping the lower boundary.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39671826/bitcoins-performance-for-the-rest-of-2024-hinges-on-this-historical-pattern">Bitcoin&#8217;s Performance For The Rest Of 2024 Hinges On This Historical Pattern</a>
Bitcoin's weekly candle did not close above the April lows of $56,500, increasing the possibility of further downside.
Decode believes that around $55,000 is a good spot for Bitcoin to hold, as it represents a strong support that is rarely broken in a bull market. It is the 38.2% retrace of the last impulse, a strong support that is rarely broken in a bull market.
Around $50,000, a 50% retrace and a break of the trend channel, would be the worst case, though the analyst expects a buy wall to support price at this price point.
Price Action: In the last 24 hours, BTC down 2% to $56,200, taking its seven-day losses to 11%.
What&#8217;s Next: The influence of&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;is expected to be thoroughly explored at Benzinga&#8217;s upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39669107/line-in-the-sand-will-make-or-break-bitcoins-bull-market-top-traders-say">&#8216;Line In The Sand&#8217; Will Make Or Break Bitcoin&#8217;s Bull Market, Top Traders Say</a></li>
</ul>
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

What Technical Analysis Says About Bitcoin's Latest Dump

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.caes.com%2F&amp;esheet=54091737&amp;newsitemid=20240708626892&amp;lan=en-US&amp;anchor=CAES&amp;index=1&amp;md5=234b9585508fd880f838989f4cfe0cca">CAES</a>, a leading provider of mission-critical advanced electronics, has received an award of $172.7 million from Raytheon Technologies (RTX) in support of a major international missile program. This award covers the next three lots of follow-on production for the missile data-link assembly.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20240708626892/en/">https://www.businesswire.com/news/home/20240708626892/en/</a>

Contracts

Raytheon Technologies Awards CAES $172M Multi-Year Contract In Support Of An International Missile Program, Covering The Next 3 Lots Of Follow-On Production For The Missile Data-Link Assembly

ServiceNow Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) shares are trading lower after Guggenheim analyst John Difucci downgraded the stock from Neutral to Sell with a <a target="_blank" href="https://www.benzinga.com/quote/NOW/analyst-ratings" rel="noreferrer noopener">$640&nbsp;price target</a>.
Needham analyst Mike Cikos reiterated ServiceNow with a Buy and a $900&nbsp;price target.
Cikos noted that in each of the past five quarters, ServiceNow has surpassed quarterly cRPO and Subscription Revenue guidance.
The analyst anticipated ServiceNow can sustain 20%-plus growth over the medium-/long-term, where the company&#8217;s unified platform architecture and value proposition drive lower TCO.
ServiceNow is benefiting from a product cycle with the launch of Pro Plus in September 2023, layering an incremental tailwind through increased ASPs, as per Cikos.
The analyst said that when accounting for the significantly larger upside in the fourth quarter of calendar 2023, the average outperformance from October 2023 to March 2024 is approximately in line with the trend line.
Management&#8217;s Subscription Revenue guidance range for $2.525 billion to $2.530 billion (+21.7%-21.9% year-on-year reported) implies modest sequential growth, where the consensus estimate of $2.252 billion assumes a $2 million quarter-on-quarter increase, which would be the lowest in the company&#8217;s history as a publicly traded company stretching back to 2012, Cikos noted.
Over the last three years, ServiceNow&#8217;s Magic Number has been 0.22 in the second quarter of calendar 2020, 0.34 in the second quarter of calendar 2021, 0.19 in the second quarter of calendar 2022, and 0.29 in the second quarter of calendar 2023. To achieve the lowest mark (0.19) over the last four years, ServiceNow would need to report $35 million of upside to the consensus estimate – or $2.560 billion in subscription revenue, per the analyst.
Based on actual foreign currency movements during the second quarter of calendar 2024, Cikos estimated a slight headwind to reported Subscription Revenue and cRPO, where both currencies were ~1% weaker during the quarter, Cikos said. As a reminder, EMEA has consistently represented roughly 25% of total revenue. The total currency headwind is likely to be further insulated due to ServiceNow&#8217;s initiation of a currency hedging program during the first quarter of calendar 2024, Cikos added.
Price Action: NOW shares traded lower by 4.74% at $768.26 at the last check Monday.
Image: Shutterstock

Analyst Color

Equities

Price Target

Reiteration

Analyst Ratings

Trading Ideas

ServiceNow Faces Mixed Analyst Opinions: Guggenheim Downgrades While Needham Sees Strong Growth Potential

COLM

Columbia Sportswear shares are trading higher after Stifel upgraded the stock from Hold to Buy and raised its price target from $84 to $92.

Needham analyst Quinn Bolton maintains Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) with a Buy and raises the price target from $85 to $94.

SIMO

Needham Maintains Buy on Silicon Motion Technology, Raises Price Target to $94

Keefe, Bruyette &amp; Woods analyst Sanjay Sakhrani maintains WEX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEX#NYSE">WEX</a>) with a Outperform and lowers the price target from $275 to $230.

Keefe, Bruyette & Woods Maintains Outperform on WEX, Lowers Price Target to $230

BENF

Beneficient shares are trading lower as the stock possibly pulls back from last week's strength.

United Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UTHR#NASDAQ">UTHR</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $326.67, a high estimate of $400.00, and a low estimate of $240.00. Surpassing the previous average price target of $299.67, the current average has increased by 9.01%.
<img src="https://www.benzinga.com/files/images/story/2024/1720461665_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of United Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$370.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$300.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Chris Shibutani</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$300.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$375.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to United Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of United Therapeutics compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of United Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of United Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UTHR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on United Therapeutics analyst ratings.</a>
<h2>Discovering United Therapeutics: A Closer Look</h2>
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
<h3>Key Indicators: United Therapeutics's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining United Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 33.7% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: United Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of 45.24%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): United Therapeutics's ROE excels beyond industry benchmarks, reaching 5.42%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.49%, the company showcases effective utilization of assets.
Debt Management: United Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UTHR

Unveiling 6 Analyst Insights On United Therapeutics

In the preceding three months, 4 analysts have released ratings for Sealed Air (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEE#NYSE">SEE</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $43.25, a high estimate of $50.00, and a low estimate of $36.00. Witnessing a positive shift, the current average has risen by 6.13% from the previous average price target of $40.75.
<img src="https://www.benzinga.com/files/images/story/2024/1720461655_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Sealed Air. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$43.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$36.00</td>
<td>$39.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Sealed Air. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Sealed Air compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Sealed Air's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Sealed Air's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SEE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sealed Air analyst ratings.</a>
<h2>Get to Know Sealed Air Better</h2>
Sealed Air is organized via two reporting segments. Food care includes food packaging products like Cryovac, Darfresh, and OptiDure aimed primarily at meats. Product care includes Sealed Air's Bubble Wrap, Instapak, Jiffy mailers, and shrink film packaging systems that cater to industrial and e-commerce applications.
<h3>Financial Insights: Sealed Air</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Challenges: Sealed Air's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -1.42%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Sealed Air's net margin excels beyond industry benchmarks, reaching 6.17%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Sealed Air's ROE stands out, surpassing industry averages. With an impressive ROE of 14.29%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Sealed Air's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.14% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 7.94, caution is advised due to increased financial risk.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Sealed Air Analyst Ratings

During the last three months, 7 analysts shared their evaluations of Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Avery Dennison, presenting an average target of $239.86, a high estimate of $253.00, and a low estimate of $220.00. Witnessing a positive shift, the current average has risen by 4.55% from the previous average price target of $229.43.
<img src="https://www.benzinga.com/files/images/story/2024/1720461644_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Avery Dennison. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$241.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Ghansham Panjabi</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Bill Selesky</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$245.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$253.00</td>
<td>$248.00</td>
</tr>
<tr>
<td>Jeffrey Zekauskas</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$220.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Matt Roberts</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$240.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Ghansham Panjabi</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Avery Dennison. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Avery Dennison compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Avery Dennison's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Avery Dennison's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AVY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Avery Dennison analyst ratings.</a>
<h2>Unveiling the Story Behind Avery Dennison</h2>
Avery Dennison manufactures pressure-sensitive materials, merchandise tags, and labels. The company also runs a specialty converting business that produces radio-frequency identification, or RFID, inlays and labels. Avery Dennison draws a significant amount of revenue from outside the United States, with international operations accounting for the majority of total sales.
<h3>Financial Milestones: Avery Dennison's Journey</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Avery Dennison's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.18% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.
Net Margin: Avery Dennison's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.01% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Avery Dennison's ROE excels beyond industry benchmarks, reaching 7.96%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Avery Dennison's ROA stands out, surpassing industry averages. With an impressive ROA of 2.09%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Avery Dennison's debt-to-equity ratio is below the industry average at 1.47, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Avery Dennison

Even when Tesla is down, you can&#8217;t count the company out, according to Jim Cramer, who suggested Monday that CEO Elon Musk is to business what legendary heavyweight Muhammad Ali <a href="https://www.benzinga.com/real-estate/24/06/39224990/muhammad-alis-childhood-home-hits-market-for-1-5-million">is to boxing</a>. 
Round 1: Monday on CNBC&#8217;s &#8220;Squawk On The Street,&#8221; Cramer suggested that you don&#8217;t want to bet against Musk, even when it looks like he&#8217;s up against the ropes. 
&#8220;He floats like a butterfly,&#8221; Cramer said, comparing Musk to Ali. &#8220;And you know how he stings?&#8221;
Tesla stock had been down more than 30% year to date before racing higher on nine consecutive green days and turning positive for the year. 
The turnaround started on the company&#8217;s last earnings call. Although Tesla missed analyst estimates, Musk reiterated his vision for the future around AI, Full Self-Driving and robotaxis, which sparked a rally in the EV stock.
Round 2: Tesla shares had been stuck in a trading range in recent months before breaking out in late June as <a href="https://www.benzinga.com/news/24/06/39505959/why-tesla-stock-is-trading-higher-wednesday-very-well-positioned-to-deliver-robust-multi-year-growth">analysts argued</a> that the company was &#8220;very well positioned to deliver robust multi-year growth." The rally accelerated in July after Tesla reported strong <a href="https://www.benzinga.com/markets/equities/24/07/39595720/tesla-deliveries-fall-for-second-straight-quarter-but-stock-takes-off-as-q2-numbers-exceed-expec">delivery numbers</a> that came in ahead of analyst estimates. 
&#8220;A lot of people felt like they had him on the ropes,&#8221; Cramer said. 
Check This Out: <a href="https://www.benzinga.com/trading-ideas/technicals/24/07/39668555/teslas-winning-streak-stock-up-22-74-in-5-days-more-room-to-run">Tesla&#8217;s Winning Streak: Stock Up 22.74% In 5 days, More Room To Run?</a>
Round 3: Cramer attributed much of the recent rally to anticipation over the company&#8217;s upcoming Robotaxi day on Aug. 8. In a note to clients last week, RBC Capital<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39419171/tesla-analysts-see-robotaxi-day-igniting-interest-in-other-autonomous-vehicle-playe"> </a><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39419171/tesla-analysts-see-robotaxi-day-igniting-interest-in-other-autonomous-vehicle-playe">highlighted robotaxis</a> as Tesla&#8217;s biggest&nbsp;valuation driver moving forward.
Cramer also believes the stock is continuing to trade higher on momentum following Musk&#8217;s pay package approval. After 77% of shareholders voted in favor of Musk&#8217;s pay package last month, the Tesla CEO said the company&#8217;s future <a href="https://www.benzinga.com/news/24/06/39324085/elon-musk-thanks-shareholders-says-tesla-starting-a-new-book-could-hit-30-trillion-valuation-hot-d-i">would be &#8220;mind-blowing.&#8221;</a>
&#8220;We&#8217;re not just opening a new chapter for Tesla, we&#8217;re starting a new book,&#8221; Musk told shareholders before suggesting that Tesla&#8217;s valuation could exceed $30 trillion in the future on the back of Optimus. 
Just last week, Musk responded to a post on X about crushing <a href="https://www.benzinga.com/top-stories/24/07/39607932/exclusive-tesla-shorts-were-profitable-this-year-until-shareholders-approved-musks-pay-package-exper">short sellers</a> betting against the future of Tesla. 
&#8220;Once Tesla fully solves autonomy and has Optimus in volume production, anyone still holding a short position will be obliterated. Even Gates,&#8221; Musk&nbsp;<a href="https://x.com/elonmusk/status/1808156026123829599" target="_blank" rel="noreferrer noopener">said</a> in the X post.
Cramer suggested that it&#8217;s not wise to bet against Tesla with Musk at the helm. &#8220;You don&#8217;t get Elon Musk on the ropes,&#8221; he said, adding that &#8220;he&#8217;s not a guy who&#8217;s in the corner.&#8221; 
TSLA Price Action: After rallying more than 45% over the last month, Tesla shares are now positive for the year. The stock was up 0.22% at $252.07 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39666123/teslas-market-share-in-china-drops-in-june-as-ev-sales-drop-by-more-than-20-over-2023">Tesla&#8217;s Market Share In China Drops In June As EV Sales Drop By More Than 20% Over 2023</a></li>
</ul>
This illustration was generated using artificial intelligence via Midjourney.

Sports

Media

General

TSLA

'He Floats Like A Butterfly': Jim Cramer Compares Elon Musk To Muhammad Ali, Explains Recent Rally In Tesla Stock

During the last three months, 5 analysts shared their evaluations of A.O. Smith (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOS#NYSE">AOS</a>), revealing diverse outlooks from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for A.O. Smith, revealing an average target of $87.6, a high estimate of $92.00, and a low estimate of $75.00. This current average has increased by 4.29% from the previous average price target of $84.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1720461634_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of A.O. Smith by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Damian Karas</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$75.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$90.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Michael Halloran</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$91.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Saree Boroditsky</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to A.O. Smith. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of A.O. Smith compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of A.O. Smith's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of A.O. Smith's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AOS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on A.O. Smith analyst ratings.</a>
<h2>Get to Know A.O. Smith Better</h2>
A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells majorly in Asian countries and operates sales offices to expand distribution and market its product portfolio.
<h3>Breaking Down A.O. Smith's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: A.O. Smith's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 1.28%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: A.O. Smith's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.08% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): A.O. Smith's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.92% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): A.O. Smith's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.62% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: A.O. Smith's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.08.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For A.O. Smith

O'Reilly Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NASDAQ">ORLY</a>) has outperformed the market over the past 15 years by 11.26% on an annualized basis producing an average annual return of 24.11%. Currently, O'Reilly Automotive has a market capitalization of $60.34 billion. 
Buying $100 In ORLY: If an investor had bought $100 of ORLY stock 15 years ago, it would be worth $2,561.42 today based on a price of $1024.57 for ORLY at the time of writing.
<h3>O'Reilly Automotive's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720461627_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ORLY

If You Invested $100 In This Stock 15 Years Ago, You Would Have $2,600 Today

Trex Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) short percent of float has risen 6.53% since its last report. The company recently reported that it has 5.38 million shares sold short, which is 5.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.47 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Trex Co Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720461622_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Trex Co has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Trex Co's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Trex Co's peer group average for short interest as a percentage of float is 4.20%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

TREX

Looking Into Trex Co's Recent Short Interest

Federated Hermes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHI#NYSE">FHI</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Federated Hermes, revealing an average target of $39.25, a high estimate of $47.00, and a low estimate of $34.00. Observing a downward trend, the current average is 0.63% lower than the prior average price target of $39.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1720461621_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Federated Hermes by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill Kirk</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>John Dunn</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Kenneth Worthington</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Adam Beatty</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Federated Hermes. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Federated Hermes compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Federated Hermes's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Federated Hermes's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FHI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Federated Hermes analyst ratings.</a>
<h2>Discovering Federated Hermes: A Closer Look</h2>
Federated provides asset management services for institutional and individual investors. The firm had $778.7 billion in managed assets at the end of March 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (74%) funds. That said, the firm's cash-management operations are expected to generate around 47% of Federated's revenue this year, compared with 29%, 13%, and 11%, respectively, for the firm's equity, fixed-income, and alternatives/multi-asset operations. From a channel perspective, the company's products are distributed via trust banks, wealth managers and retail broker/dealers (64% of AUM), institutional investors (28%), and international clients (8%).
<h3>Federated Hermes's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Federated Hermes showcased positive performance, achieving a revenue growth rate of 3.71% as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Federated Hermes's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 18.07%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Federated Hermes's ROE excels beyond industry benchmarks, reaching 6.3%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Federated Hermes's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.42%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.4.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Federated Hermes Stands With Analysts

Cenovus Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVE#NYSE">CVE</a>) has outperformed the market over the past 5 years by 2.34% on an annualized basis producing an average annual return of 15.39%. Currently, Cenovus Energy has a market capitalization of $36.52 billion. 
Buying $1000 In CVE: If an investor had bought $1000 of CVE stock 5 years ago, it would be worth $2,074.15 today based on a price of $19.58 for CVE at the time of writing.
<h3>Cenovus Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1720461621_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.